Fang He1, J Philippe York2, Sherilyn Gordon Burroughs2, Lidong Qin2, Jintang Xia1, De Chen1, Eamonn M Quigley2, Paul Webb2, Gene D LeSage3, Xuefeng Xia4. 1. The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 2. Houston Methodist Research Institute, Weill Cornell School of Medicine, Houston, TX, USA. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, East Tennessee State University, Johnson City, TN, USA. 4. The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Houston Methodist Research Institute, Weill Cornell School of Medicine, Houston, TX, USA. Electronic address: xxia2@tmhs.org.
Abstract
BACKGROUND: Peroxisome proliferator-activated receptor δ (PPARδ) is a versatile regulator of distinct biological processes and overexpression of PPARδ in cancer may be partially related to its suppression of its own co-regulators. AIMS: To determine whether recruited suppressor proteins bind to and regulate PPARδ expression, activity and PPARδ-dependent cholangiocarcinoma proliferation. METHODS: Yeast two-hybrid assays were done using murine PPARδ as bait. PPARδ mRNA expression was determined by qPCR. Protein expression was measured by western blot. Immunohistochemistry and fluorescence microscopy were used to determine PPARδ expression and co-localization with NDP Kinase alpha (NM23-H2). Cell proliferation assays were performed to determine cell numbers. RESULTS: Yeast two-hybrid screening identified NM23-H2 as a PPARδ binding protein and their interaction was confirmed. Overexpressed PPARδ or treatment with the agonist GW501516 resulted in increased cell proliferation. NM23-H2 siRNA activated PPARδ luciferase promoter activity, upregulated PPARδ RNA and protein expression and increased GW501516-stimulated CCA growth. Overexpression of NM23-H2 inhibited PPARδ luciferase promoter activity, downregulated PPARδ expression and AKT phosphorylation and reduced GW501516-stimulated CCA growth. CONCLUSIONS: We report the novel association of NM23-H2 with PPARδ and the negative regulation of PPARδ expression by NM23-H2 binding to the C-terminal region of PPARδ. These findings provide evidence that the metastasis suppressor NM23-H2 is involved in the regulation of PPARδ-mediated proliferation.
BACKGROUND:Peroxisome proliferator-activated receptor δ (PPARδ) is a versatile regulator of distinct biological processes and overexpression of PPARδ in cancer may be partially related to its suppression of its own co-regulators. AIMS: To determine whether recruited suppressor proteins bind to and regulate PPARδ expression, activity and PPARδ-dependent cholangiocarcinoma proliferation. METHODS: Yeast two-hybrid assays were done using murinePPARδ as bait. PPARδ mRNA expression was determined by qPCR. Protein expression was measured by western blot. Immunohistochemistry and fluorescence microscopy were used to determine PPARδ expression and co-localization with NDP Kinase alpha (NM23-H2). Cell proliferation assays were performed to determine cell numbers. RESULTS: Yeast two-hybrid screening identified NM23-H2 as a PPARδ binding protein and their interaction was confirmed. Overexpressed PPARδ or treatment with the agonist GW501516 resulted in increased cell proliferation. NM23-H2 siRNA activated PPARδ luciferase promoter activity, upregulated PPARδ RNA and protein expression and increased GW501516-stimulated CCA growth. Overexpression of NM23-H2 inhibited PPARδ luciferase promoter activity, downregulated PPARδ expression and AKT phosphorylation and reduced GW501516-stimulated CCA growth. CONCLUSIONS: We report the novel association of NM23-H2 with PPARδ and the negative regulation of PPARδ expression by NM23-H2 binding to the C-terminal region of PPARδ. These findings provide evidence that the metastasis suppressor NM23-H2 is involved in the regulation of PPARδ-mediated proliferation.
Authors: Tania M Welzel; Katherine A McGlynn; Ann W Hsing; Thomas R O'Brien; Ruth M Pfeiffer Journal: J Natl Cancer Inst Date: 2006-06-21 Impact factor: 13.506
Authors: P Sarraf; E Mueller; D Jones; F J King; D J DeAngelo; J B Partridge; S A Holden; L B Chen; S Singer; C Fletcher; B M Spiegelman Journal: Nat Med Date: 1998-09 Impact factor: 53.440
Authors: Una Kjällquist; Rikard Erlandsson; Nicholas P Tobin; Amjad Alkodsi; Ikram Ullah; Gustav Stålhammar; Eva Karlsson; Thomas Hatschek; Johan Hartman; Sten Linnarsson; Jonas Bergh Journal: BMC Cancer Date: 2018-02-12 Impact factor: 4.430